The Food and Drug Administration (FDA) yesterday issued a special import permit for Paxlovid, an oral antiviral drug developed by Pfizer Inc to treat COVID-19, and the first shipment is expected to arrive before March, the Central Epidemic Command Center (CECC) said.
Pfizer’s import permit application was approved after a specialists’ meeting at the agency yesterday morning, FDA Director Wu Shou-mei (吳秀梅) said.
Having assessed Paxlovid’s therapeutic effect, safety, risks and benefits, and considering the domestic COVID-19 situation and public health demand, the specialists agreed to grant special approval to the drug, according to Article 48-2 of the Pharmaceutical Affairs Act (藥事法), she said.
Photo: Reuters
Pfizer is required to implement a risk management plan during the special permit period to ensure the drug’s safety, she added.
Paxlovid should be administered after a diagnosis of COVID-19 and within five days of the onset of symptoms, for adults who are at high of risk developing severe illness from the virus and children aged 12 or older weighing at least 40kg with mild to moderate symptoms, she said.
The drug is administered as three tablets — two tablets of PF-07321332 (150mg) and one tablet of ritonavir (100mg) — which are packaged together to take orally twice daily for a five-day course, Wu said, adding that not following the course could affect the treatment.
PF-07321332 works by blocking the activity of an enzyme that SARS-CoV-2 needs to multiply, and ritonavir helps slow the metabolism of PF-07321332, allowing it to remain active at higher concentrations in the blood for extended periods, she said.
Minister of Health and Welfare Chen Shih-chung (陳時中), who heads the CECC, said that the ministry has signed a procurement contract with Pfizer to purchase 20,000 courses of Paxlovid, and that the first batch is expected to arrive before March.
Paxlovid is the second oral antiviral COVID-19 medication to obtain a special import permit from the FDA, after the CECC on Wednesday said that a permit was issued to US drugmaker Merck’s Taiwan branch for its molnupiravir antiviral drug.
NETWORK-MAPPING PROJECT: The database contains 170 detailed files of Taiwanese politicians and about 23 million records of household registration data in Taiwan China has developed a network-mapping project targeting political figures and parties in Taiwan to monitor public opinion during elections and to craft tailored influence campaigns aimed at dividing Taiwanese society, according to documents leaked by Chinese technology firm GoLaxy (中科天璣). The documents, collected by Taipei-based Doublethink Lab, showed a database was specifically created to gather detailed information on Taiwanese political figures, including their political affiliations, job histories, birthplaces, residences, education, religion and a brief biography about them. Several notable Taiwanese politicians are in the database, including President William Lai (賴清德), former president Tsai Ing-wen (蔡英文), Minister of Foreign Affairs Lin Chia-lung (林佳龍),
RECOGNITION: Former Fijian prime minister Mahendra Chaudhry said that Taiwan’s New Southbound Policy serves as a stabilizing force in the Indo-Pacific region Taiwan can lead the unification of the Chinese people, Nobel Peace Prize laureate and former Polish president Lech Walesa said in Taipei yesterday, adding that as the world order is changing, peaceful discussion would find good solutions, and that the use of force and coercion would always fail. Walesa made the remarks during his keynote address at a luncheon of the Yushan Forum in Taipei, titled “Indo-Pacific Partnership Prospects: Taiwan’s Values, Technology and Resilience,” organized by the Taiwan-Asia Exchange Foundation with the Ministry of Foreign Affairs. Walesa said that he had been at the forefront of a big peaceful revolution and “if
North Korea tested nuclear-capable rocket launchers, state media reported yesterday, a day after Seoul detected the launch of about 10 ballistic missiles. The test comes after South Korean and US forces launched their springtime military drills, due to run until Thursday. North Korean leader Kim Jong-un on Saturday oversaw the testing of the multiple rocket launcher system (MRLS), the Korean Central News Agency (KCNA) said. The test involved 12 600mm-caliber ultra-precision multiple rocket launchers and two artillery companies, it said. Kim said the drill gave Pyongyang’s enemies, within the 420km striking range, a sense of “uneasiness” and “a deep understanding
UPGRADED MISSILE: The Chungshan Institute of Science and Technology is reportedly to conduct a live-fire test of the Hsiung Feng III anti-ship missile on Thursday next week The US Army is planning to build new facilities to boost explosives production and strengthen its supply chain, a move aimed at addressing munitions shortages and supporting obligations to partners including Taiwan, Ukraine and Israel, Defense News reported. The army has issued a sources sought notice for a proposed Center of Excellence at the Blue Grass Army Depot in Kentucky, the report said. The facility would serve as a hub within the US industrial base for the production of key military explosives, including research department explosives (RDX) and high melting explosives (HMX), while also supporting research and development of next-generation materials. The proposed
RSS